- Home
- DRUG vs AMCX Comparison
DRUG vs AMCX Comparison
Compare DRUG & AMCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- AMCX
- Stock Information
- Founded
- DRUG 2019
- AMCX 1980
- Country
- DRUG United States
- AMCX United States
- Employees
- DRUG N/A
- AMCX N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- AMCX Cable & Other Pay Television Services
- Sector
- DRUG Health Care
- AMCX Telecommunications
- Exchange
- DRUG Nasdaq
- AMCX Nasdaq
- Market Cap
- DRUG 345.6M
- AMCX 312.4M
- IPO Year
- DRUG N/A
- AMCX 2011
- Fundamental
- Price
- DRUG $45.43
- AMCX $8.20
- Analyst Decision
- DRUG Strong Buy
- AMCX Sell
- Analyst Count
- DRUG 9
- AMCX 5
- Target Price
- DRUG $81.67
- AMCX $6.50
- AVG Volume (30 Days)
- DRUG 70.6K
- AMCX 408.7K
- Earning Date
- DRUG 08-11-2025
- AMCX 11-07-2025
- Dividend Yield
- DRUG N/A
- AMCX N/A
- EPS Growth
- DRUG N/A
- AMCX N/A
- EPS
- DRUG N/A
- AMCX N/A
- Revenue
- DRUG N/A
- AMCX $2,354,176,000.00
- Revenue This Year
- DRUG N/A
- AMCX N/A
- Revenue Next Year
- DRUG N/A
- AMCX N/A
- P/E Ratio
- DRUG N/A
- AMCX N/A
- Revenue Growth
- DRUG N/A
- AMCX N/A
- 52 Week Low
- DRUG $0.94
- AMCX $5.41
- 52 Week High
- DRUG $79.02
- AMCX $10.60
- Technical
- Relative Strength Index (RSI)
- DRUG 57.15
- AMCX 54.19
- Support Level
- DRUG $39.70
- AMCX N/A
- Resistance Level
- DRUG $49.49
- AMCX $8.48
- Average True Range (ATR)
- DRUG 3.14
- AMCX 0.27
- MACD
- DRUG 0.13
- AMCX -0.23
- Stochastic Oscillator
- DRUG 64.66
- AMCX 96.70
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About AMCX AMC Networks Inc.
AMC Networks owns several linear pay-TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network, reached 60 million pay-TV households in the US at the end of 2024. The firm also had nearly 12.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.